Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration.
Aflibercept
Age-related macular degeneration
Long-term outcome
Treat-and-extend
Journal
Japanese journal of ophthalmology
ISSN: 1613-2246
Titre abrégé: Jpn J Ophthalmol
Pays: Japan
ID NLM: 0044652
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
05
2020
accepted:
28
08
2020
pubmed:
8
11
2020
medline:
19
8
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD). Retrospective observational study. Data of eyes with recurrent AMD previously treated with anti-vascular endothelial growth factor agents or photodynamic therapy and had started aflibercept treatment using a TAE regimen for the first time were collected. Best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central foveal thickness (CFT), and central choroidal thickness (CCT) were analyzed. Of 47 consecutive eyes, 30 of the 47 eyes completed a 4-year follow-up. The mean BCVA (logMAR) was sustained over the 4 years (0.37 at baseline, 0.36 at 1 year, 0.36 at 2 years, 0.41 at 3 years, and 0.43 at 4 years, P = 0.21). Of the 30 eyes that completed the follow-up, BCVA of two eyes deteriorated by 0.3 logMAR or more at 4 years. At 4 years, 67% of eyes had extended treatment intervals to > 8 weeks, and 47% of eyes had extended intervals to > 12 weeks. Exudative changes in the macula, seen in all eyes at baseline, were only seen in 50% of the eyes at 4 years. The mean CFT and CCT decreased significantly at 4 years from 332 μm to 248 μm and from 218 μm to 183 μm, respectively. In clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4 years even in recurrent cases of AMD.
Identifiants
pubmed: 33159611
doi: 10.1007/s10384-020-00783-8
pii: 10.1007/s10384-020-00783-8
doi:
Substances chimiques
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-76Références
Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26–33.
doi: 10.1007/s10384-018-0623-4
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.
doi: 10.1056/NEJMoa054481
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.
doi: 10.1056/NEJMoa062655
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.
doi: 10.1016/j.ophtha.2008.10.018
Group C, Martin DF, Maguire MG, Ying G-S, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.
doi: 10.1056/NEJMoa1102673
Singer MA, Awh CC, Sadda SV, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–83.
doi: 10.1016/j.ophtha.2011.12.016
Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.
doi: 10.1016/j.ophtha.2013.03.046
Group CoA-rMDTTCR, Maguire MG, Martin DF, Ying G-SS, Jaffe GJ, Daniel E, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61.
doi: 10.1016/j.ophtha.2016.03.045
Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration trex-amd 1-year results. Ophthalmology. 2015;122:2514–22.
doi: 10.1016/j.ophtha.2015.08.009
Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina. 2010;30:1368–75.
doi: 10.1097/IAE.0b013e3181d50cbf
Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80.
doi: 10.1016/j.ajo.2007.02.024
Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–40.
doi: 10.1016/j.ophtha.2010.02.032
Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration 2-year results of the trex-amd study. Ophthalmol Retina. 2017;1:314–21.
doi: 10.1016/j.oret.2016.12.004
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser P, Nguyen Q, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.
doi: 10.1016/j.ophtha.2012.09.006
Eleftheriadou M, Gemenetzi M, Lukic M, Sivaprasad S, Hykin PG, Hamilton RD, et al. Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: evidence from a clinical setting. Ophthalmol Ther. 2018;7:361–8.
doi: 10.1007/s40123-018-0139-5
Morimoto M, Matsumoto H, Mimura K, Akiyama H. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1891–7.
doi: 10.1007/s00417-017-3718-6
Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol. 2018;62:144–50.
doi: 10.1007/s10384-018-0562-0
Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, et al. Two year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018;38:20–8.
doi: 10.1097/IAE.0000000000001496
Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. Ophthalmol Retina. 2019;3:393–9.
doi: 10.1016/j.oret.2019.01.018
Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:29–35.
doi: 10.1016/j.ajo.2013.03.030
Singh RP, Srivastava S, Ehlers JP, Bedi R, Schachat AP, Kaiser PK. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol. 2014;98:i22–7.
doi: 10.1136/bjophthalmol-2013-304798
Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol. 2016;100:1640–5.
doi: 10.1136/bjophthalmol-2015-308090
Kvannli L, Krohn J. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2017;95:678–82.
doi: 10.1111/aos.13356
Giannakaki-Zimmermann H, Ebneter A, Munk MR, Wolf S, Zinkernagel MS. Outcomes when switching from a pro re nata regimen to a treat and extend regimen using aflibercept in neovascular age-related macular degeneration. Ophthalmologica. 2017;236:201–6.
doi: 10.1159/000452929
Spooner K, Hong T, Wijeyakumar W, Chang AA. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clin Ophthalmol. 2017;11:161–77.
doi: 10.2147/OPTH.S125676
Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:914–7.
doi: 10.1136/bjophthalmol-2015-306987
Augsburger M, Sarra G-MM, Imesch P. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol. 2019;257:1889–95.
doi: 10.1007/s00417-019-04404-0
Adrean SD, Chaili S, Grant S, Pirouz A. Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat–extend–stop protocol. Ophthalmol Retina. 2018;2:225–30.
doi: 10.1016/j.oret.2017.07.009
Nguyen V, Vaze A, Fraser-Bell S, Arnold J, Essex RW, Barthelmes D, et al. Outcomes of suspending vegf inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months. Ophthalmol Retina. 2019;3:623–8.
doi: 10.1016/j.oret.2019.05.013
Hosokawa M, Morizane Y, Hirano M, Kimura S, Kumase F, Shiode Y, et al. One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2017;61:150–8.
doi: 10.1007/s10384-016-0492-7
Yamamoto A, Okada AA, Nakayama M, Yoshida Y, Kobayashi H. One-year outcomes of a treat-and-extend regimen of aflibercept for exudative age-related macular degeneration. Ophthalmologica. 2017;237:139–44.
doi: 10.1159/000458538
Spaide RF, Jaffe GJ, Sarraf D, Freund BK, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data. Ophthalmology. 2019;127:616–36.
doi: 10.1016/j.ophtha.2019.11.004
Suzuki M, Nagai N, Izumi-Nagai K, Shinoda H, Koto T, Uchida A, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014;98:1186–91.
doi: 10.1136/bjophthalmol-2013-304670
Nakano Y, Kataoka K, Takeuchi J, Fujita A, Kaneko H, Shimizu H, et al. Vascular maturity of type 1 and type 2 choroidal neovascularization evaluated by optical coherence tomography angiography. PLoS ONE. 2019;14:e0216304.
doi: 10.1371/journal.pone.0216304
Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol. 2018;192:184–97.
doi: 10.1016/j.ajo.2018.05.026
Ito A, Matsumoto H, Morimoto M, Mimura K, Akiyama H. Two-year outcomes of a treat-and-extend regimen using intravitreal aflibercept injections for typical age-related macular degeneration. Ophthalmologica. 2017;238:236–42.
doi: 10.1159/000479937
Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, et al. Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study. Ophthalmol Retina. 2020;4:767–76.
doi: 10.1016/j.oret.2020.03.010